On the evening of December 24, Hengrui Pharmaceutical announced that recently, the company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd.'s injectable SHR-A1904 were included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. According to information, injectable SHR-A1904 is an antibody drug conjugate targeting Claudin18.2 independently developed by Hengrui Pharmaceutical and has intellectual property rights. It is worth noting that recently, many innovative pharmaceutical companies such as Corning Jerry, Bailey Tianheng, and Colon Botai have accelerated breakthroughs and made new progress in the field of ADC research and development. Industry insiders said that in the global wave of ADC drug development innovation, Chinese companies have become global ADC innovation engines and are expected to benefit in the long term. As a revolutionary therapy in the field of tumor treatment, ADC drugs have great potential for market growth.

On the evening of December 24, Hengrui Pharmaceutical announced that recently, the company and its subsidiary Shanghai Hengrui Pharmaceutical Co., Ltd.'s injectable SHR-A1904 were included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. According to information, injectable SHR-A1904 is an antibody drug conjugate targeting Claudin18.2 independently developed by Hengrui Pharmaceutical and has intellectual property rights. It is worth noting that recently, many innovative pharmaceutical companies such as Corning Jerry, Bailey Tianheng, and Colon Botai have accelerated breakthroughs and made new progress in the field of ADC research and development. Industry insiders said that in the global wave of ADC drug development innovation, Chinese companies have become global ADC innovation engines and are expected to benefit in the long term. As a revolutionary therapy in the field of tumor treatment, ADC drugs have great potential for market growth.